Vivos' High-Stakes Pitch: A New Dawn for Sleep Apnea or a Fight for Survival?

NEW YORK, NY – June 08, 2026 – When Kirk Hunstman, CEO of Vivos Therapeutics, steps up to the podium at The Small Cap Showcase in New York City tomorrow, he’ll be doing more than delivering a corporate presentation. He’ll be making a case for the very future of his company at a moment of profound opportunity and significant financial pressure. The Littleton, Colorado-based firm is armed with a technology that promises to reshape the treatment of obstructive sleep apnea (OSA), a condition affecting a staggering one billion people worldwide. Yet, as Vivos courts investors, it does so under the shadow of a recent Nasdaq non-compliance notice and an urgent need to shore up its balance sheet.

This is the complex world of medical innovation, where a potentially life-changing product must navigate the unforgiving currents of capital markets. For Vivos, the pitch to investors is not just about growth; it’s about survival and the chance to bring its unique solution to a market desperate for alternatives.

Navigating the Tightrope of Innovation and Capital

On the surface, the announcement of Vivos’ participation in an investor showcase is standard corporate procedure. The event connects emerging companies with pre-qualified investors, offering a forum for discovery and networking. For Vivos, however, the timing is critical. Just last week, on June 5, the company received a notice from Nasdaq that its stock had traded below the required $1.00 minimum for 30 consecutive days, triggering a 180-day period to regain compliance. Compounding this, the company is also working to meet the exchange’s stockholders' equity requirements.

This isn’t a sign of a company in quiet retreat. Instead, Vivos is actively maneuvering to solidify its financial foundation. On the same day it received the Nasdaq notice, it announced a binding agreement with its senior lender to convert up to $4.5 million in debt into equity. This strategic move, contingent on the company successfully raising new capital, is designed to reduce debt, improve cash flow, and boost its equity position. The presentation in New York is a pivotal part of that capital-raising effort.

Investors will be listening intently. They will hear the story of a company whose stock has fallen over 57% year-to-date, but also one whose leadership is making decisive, if challenging, moves to right the ship. They will weigh the considerable risks against the immense potential of the market Vivos aims to capture.

Beyond the Mask: A New Paradigm for OSA Treatment

To understand the excitement around Vivos, one must first understand the problem with the current standard of care for sleep apnea. For decades, the primary treatment has been the Continuous Positive Airway Pressure (CPAP) machine. While effective, the device is notoriously burdensome. Patients are tethered to a machine via a mask, and the constant pressurized air can be uncomfortable and noisy. Compliance is a massive issue, with many users abandoning the treatment altogether, leaving their chronic condition unmanaged.

Vivos proposes a radically different approach. Its proprietary solution, The Vivos Method, doesn't just manage symptoms during sleep; it aims to correct the underlying anatomical issues that cause OSA. Using a set of custom oral appliances, the treatment works over a period of about 9 to 12 months to gradually remodel and expand the airway. The company’s tagline, “Breathe New Life,” speaks to this goal of a lasting, non-surgical solution.

The company’s technology has achieved what no other oral appliance has. Vivos’ CARE devices are the first and only to receive FDA 510(k) clearance for treating severe OSA in adults. This breakthrough moves oral appliances from a treatment for mild-to-moderate cases into the mainstream of sleep medicine, offering a viable alternative to CPAP or invasive surgery for the most serious patients. Furthermore, its Vivos DNA appliance is the first oral medical device cleared by the FDA for treating moderate-to-severe OSA in children, addressing a critical and underserved pediatric health issue.

The Billion-Person Market and the Clinical Evidence

The market opportunity is almost unfathomably large. With over a billion people affected globally and an estimated 80% of them undiagnosed, OSA represents a vast and growing public health crisis. It’s linked to serious comorbidities like hypertension, heart disease, and diabetes. Vivos is positioning itself as a key solution to this silent epidemic.

To back its claims, the company points to compelling clinical data. The FDA clearance for severe OSA was supported by a trial where 80% of patients saw their condition improve by at least one classification level (e.g., from severe to moderate), and 97% showed some improvement. An independent patient survey reported that 97% of patients were satisfied with their treatment outcome. In the pediatric space, a multicenter trial showed that 77% of children experienced at least a 50% reduction in OSA severity, offering a non-surgical alternative to tonsillectomies.

This clinical validation is the core of the value proposition Hunstman will present to investors. It’s the evidence that Vivos is not just another device company but a potential disruptor in a multi-billion-dollar market. However, the treatment comes at a significant cost, often not fully covered by insurance, and as with any medical intervention, patient outcomes can vary, a reality that tempers the otherwise glowing reports.

A New Blueprint for Growth

Recognizing the challenges of introducing a new treatment paradigm, Vivos has also evolved its business model. The 2025 acquisition of The Sleep Center of Nevada signaled a strategic shift from being solely a device manufacturer to becoming an integrated healthcare services company. By owning and operating sleep centers, Vivos can control the entire patient journey, from diagnosis to treatment, ensuring its methods are implemented correctly and capturing a larger share of the revenue.

This vertical integration is a bold strategy. It allows the company to build a scalable model for patient care and generate valuable real-world data, but it also adds operational complexity. For investors, this dual identity as both a technology innovator and a healthcare provider presents a more intricate, but potentially more powerful, long-term growth story.

As Vivos executives meet with investors, they will be selling this multifaceted vision. It is a story of profound medical need, breakthrough technology, and a strategic pivot to capture a market waiting for a better solution. The question now is whether the financial community will see past the immediate balance sheet pressures to fund what could be the next chapter in sleep medicine.